Drug profile · INN
cefdinir
OMNICEF
cefdinir (OMNICEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — cefdinir
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
cefdinir (OMNICEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cefdinir?
cefdinir (OMNICEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cefdinir?
OMNICEF is a marketed brand name for cefdinir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cefdinir?
cefdinir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.